bioAffinity Technologies, Inc. announced on October 10, 2024, the appointment of J. Michael Edwards as its new Chief Financial Officer. This executive change is a key development for the biotechnology company as it continues to advance its noninvasive diagnostic test for early-stage lung cancer, CyPath Lung.
Mr. Edwards previously served as the company's CFO from 2019 to 2023, bringing prior experience with bioAffinity Technologies to his renewed role. His expertise is expected to support the company's financial management and strategic growth initiatives.
The appointment of a seasoned financial leader is important for guiding the company's capital allocation, financial reporting, and overall fiscal health as it focuses on commercializing CyPath Lung and managing its operational expenses.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.